Overview

Renal Transplantation and Raltegravir in HIV-Infected Patients

Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the incidence of acute renal graft rejection 6 months after transplantation in HIV-infected patients under three antiretroviral drugs regimen including Raltegravir.
Phase:
Phase 3
Details
Lead Sponsor:
ANRS, Emerging Infectious Diseases
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Raltegravir Potassium